Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jan 10;12(1):11.
doi: 10.3390/ph12010011.

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

Affiliations
Review

The Therapeutic Potential of Naringenin: A Review of Clinical Trials

Bahare Salehi et al. Pharmaceuticals (Basel). .

Abstract

Naringenin is a flavonoid belonging to flavanones subclass. It is widely distributed in several Citrus fruits, bergamot, tomatoes and other fruits, being also found in its glycosides form (mainly naringin). Several biological activities have been ascribed to this phytochemical, among them antioxidant, antitumor, antiviral, antibacterial, anti-inflammatory, antiadipogenic and cardioprotective effects. Nonetheless, most of the data reported have been obtained from in vitro or in vivo studies. Although some clinical studies have also been performed, the main focus is on naringenin bioavailability and cardioprotective action. In addition, these studies were done in compromised patients (i.e., hypercholesterolemic and overweight), with a dosage ranging between 600 and 800 μM/day, whereas the effect on healthy volunteers is still debatable. In fact, naringenin ability to improve endothelial function has been well-established. Indeed, the currently available data are very promising, but further research on pharmacokinetic and pharmacodynamic aspects is encouraged to improve both available production and delivery methods and to achieve feasible naringenin-based clinical formulations.

Keywords: cardiovascular diseases; chemopreventive; citrus; flavanones; flavonoids; nutraceutics; phytochemicals.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Naringenin biosynthesis.

References

    1. Mbaveng A.T., Zhao Q., Kuete V. Toxicological Survey of African Medicinal Plants. Elsevier; New York, NY, USA: 2014. Chapter 20—Harmful and protective effects of phenolic compounds from African medicinal plants; pp. 577–609.
    1. Jadeja R.N., Devkar R.V. Polyphenols in Human Health and Disease. Academic Press; San Diego, CA, USA: 2014. Polyphenols and flavonoids in controlling non-alcoholic steatohepatitis; pp. 615–623.
    1. Zobeiri M., Belwal T., Parvizi F., Naseri R., Farzaei M.H., Nabavi S.F., Sureda A., Nabavi S.M. Naringenin and its nano-formulations for fatty liver: Cellular modes of action and clinical perspective. Curr. Pharm. Biotechnol. 2018;19:196–205. doi: 10.2174/1389201019666180514170122. - DOI - PubMed
    1. Soltana H., De Rosso M., Lazreg H., Vedova A.D., Hammami M., Flamini R. LC-QTOF characterization of non-anthocyanic flavonoids in four Tunisian fig varieties. J. Mass Spectrom. JMS. 2018;53:817–823. doi: 10.1002/jms.4209. - DOI - PubMed
    1. Wilcox L.J., Borradaile N.M., Huff M.W. Antiatherogenic properties of naringenin, a citrus flavonoid. Cardiovasc. Drug Rev. 1999;17:160–178. doi: 10.1111/j.1527-3466.1999.tb00011.x. - DOI

LinkOut - more resources